v3.26.1
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Costs and expenses:    
Research and development $ 10,839,150 $ 10,513,579
Selling, general and administrative 7,376,123 5,249,291
Change in fair value contingent consideration (373,354) (1,164,864)
Total costs and expenses 17,841,919 14,598,006
Loss from operations (17,841,919) (14,598,006)
Interest income 1,461,079 919,271
Net loss (16,380,840) (13,678,735)
Other comprehensive income (loss), net of tax    
Unrealized gain (loss) on marketable securities (48,095) 36,281
Comprehensive loss $ (16,428,935) $ (13,642,454)
Net loss per share - basic $ (0.1) $ (0.15)
Net loss per share - diluted $ (0.1) $ (0.15)
Weighted-average number of shares_ basic 172,306,932 89,537,171
Weighted-average number of shares_ diluted 172,306,932 89,537,171

Source